ERBB2 and metabolic dysfunction-associated steatohepatitis: Of note, CYPD has previously been shown to promote (rather than inhibit) hepatocellular carcinogenesis in mice with non-alcoholic steatohepatitis [51] as well HR+HER2+ mammary carcinogenesis as driven by the MMTV-PyMT construct [52].